Allakos (ALLK)
(Delayed Data from NSDQ)
$1.20 USD
-0.09 (-6.98%)
Updated May 10, 2024 04:00 PM ET
After-Market: $1.21 +0.01 (0.83%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
ALLK 1.20 -0.09(-6.98%)
Will ALLK be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ALLK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALLK
Allakos (ALLK): Strong Industry, Solid Earnings Estimate Revisions
Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update
ALLK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Allakos Inc. (ALLK) is Poised for a Turnaround After Losing -61.36% in 4 Weeks
Allakos (ALLK) Plummets 60% on Ending Development of Lead Drug
Is Allakos (ALLK) Stock Outpacing Its Medical Peers This Year?
Other News for ALLK
NOTV, BFRI and CPOP among pre-market losers
Analysts Have Conflicting Sentiments on These Healthcare Companies: Electrocore (ECOR), Disc Medicine (IRON) and Allakos (ALLK)
Piper Sandler Sticks to Their Buy Rating for Allakos (ALLK)
Barclays Sticks to Its Sell Rating for Allakos (ALLK)
Allakos Inc. Reports Increased Losses in Q1 2024, Misses Analyst Earnings Predictions